Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Expanded_access × avelumab × Dermatologic × Clear all

Status

Approved for marketing 1

Sponsor Class

Study Type

Interventional 23 Expanded_access 1

Sponsor

Cancer Type

Conditions

Carcinoma, Merkel Cell 1

Interventions

trametinib 3 dabrafenib 3 talimogene laherparepvec 2 pembrolizumab 2 Nivolumab 2 Ipilimumab 2 ulixertinib 1 tebentafusp 1 pegilodecakin 1 omaveloxolone 1 methyl 5-aminolevulinate 1 efineptakin alfa 1 cemiplimab 1 balstilimab 1 avelumab 1 aldesleukin 1 Rose Bengal 1 Melphalan 1 HhAntag691 1 Cyclophosphamide 1 Brentuximab Vedotin 1 AM0010 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03089658 2019-10-09

Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC)

Merck KGaA, Darmstadt, Germany

Approved for marketing

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡